Key Takeaway In the phase III ELATIVE trial, elafibranor maintained robust biochemical efficacy in patients with PBC and inadequate response or intolerance to UDCA, with 64.3% achieving biochemical response at Week 104 versus 0% with placebo. Longer-term open-label data showed sustained responses through 156 weeks, stable non-invasive fibrosis measures, numerical improvements in fatigue and pruritus,...